{"entity":{"id":"enoxaparin","kind":"drug","name":"Enoxaparin","aka":["enoxaparin sodium","Inhixa"],"tldr":"Enoxaparin is a blood-thinning injection given under the skin. People with cancer have it to prevent clots after surgery or to treat a clot in a leg vein or the lungs.","summary":"The Lovenox label covers prophylaxis of deep vein thrombosis in abdominal, hip and knee surgery and in acutely ill medical patients, inpatient and outpatient treatment of acute DVT, and acute coronary syndromes. ITAC 2022 recommends a low-molecular-weight heparin (LMWH) for the initial treatment of established venous thromboembolism in people with cancer when creatinine clearance is at least 30 mL/min (grade 1A), and prefers LMWHs over vitamin K antagonists for treatment (1A); where a twice-daily regimen is needed, it says only enoxaparin (1 mg/kg twice daily) can be used. The NDA was first approved on 29 March 1993.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Enoxaparin_sodium","links":[{"label":"US label (DailyMed): Lovenox","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d263380-4f44-4fd8-aa2a-e69702ab258f"},{"label":"Farge et al., 2022 international clinical practice guidelines (ITAC) for the treatment and prophylaxis of venous thromboembolism in patients with cancer (Lancet Oncol 2022)","url":"https://doi.org/10.1016/S1470-2045(22)00160-7"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["dalteparin","tinzaparin","apixaban","rivaroxaban","edoxaban","warfarin"],"cancers":[],"sections":[],"technologies":["cancer-associated-thrombosis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["vte"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Lovenox / Clexane","modality":"Low-molecular-weight heparin (injection)","supportive":true,"mechanism":"A low-molecular-weight heparin: potentiates antithrombin, mainly against activated factor X.","approvals":[{"region":"US","year":1993,"indication":"Prophylaxis of DVT in abdominal, hip and knee surgery and in medical patients with restricted mobility; treatment of acute DVT; acute coronary syndromes","note":"Year is the original NDA 020164 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/enoxaparin/","neighbours":{"drug":[{"id":"apixaban","kind":"drug","name":"Apixaban","route":"/drugs/apixaban/"},{"id":"dalteparin","kind":"drug","name":"Dalteparin","route":"/drugs/dalteparin/"},{"id":"edoxaban","kind":"drug","name":"Edoxaban","route":"/drugs/edoxaban/"},{"id":"rivaroxaban","kind":"drug","name":"Rivaroxaban","route":"/drugs/rivaroxaban/"},{"id":"tinzaparin","kind":"drug","name":"Tinzaparin","route":"/drugs/tinzaparin/"},{"id":"warfarin","kind":"drug","name":"Warfarin","route":"/drugs/warfarin/"}],"technology":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/"}],"term":[{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/"}]}}